ABSTRACT
Although statins are remarkably effective, they are still underprescribed because of concerns about muscle toxicity. We review the aspects of statin myopathy that are important to the primary care physician and provide a guide for evaluating patients on statins who present with muscle complaints. We outline the differential diagnosis, the risks and benefits of statin therapy in patients with possible toxicity, and the subsequent treatment options.
- Copyright © 2011 The Cleveland Clinic Foundation. All Rights Reserved.
Jump to section
Related Articles
Cited By...
- Drug-induced cytotoxicity prediction in muscle cells, an application of the Cell Painting assay
- Statins for the primary prevention of cardiovascular disease: an overview of systematic reviews
- Statin Therapy as Primary Prevention in Exercising Adults: Best Evidence for Avoiding Myalgia
- The Case For and Against a Coronary Artery Calcium Trial: Means, Motive, and Opportunity
- Statin therapy in patients with cirrhosis
- Rhabdomyolysis: Pathogenesis, Diagnosis, and Treatment
- Experimental Nonalcoholic Steatohepatitis Increases Exposure to Simvastatin Hydroxy Acid by Decreasing Hepatic Organic Anion Transporting Polypeptide Expression
- Perspective on the 2013 American Heart Association/American College of Cardiology Guideline for the Use of Statins in Primary Prevention of Low-Risk Individuals
- Authors' reply to Huffman and colleagues
- Proximal myopathy: diagnostic approach and initial management
- Comparative Tolerability and Harms of Individual Statins: A Study-Level Network Meta-Analysis of 246 955 Participants From 135 Randomized, Controlled Trials
- Reinitiation of Statins After Statin-Associated Musculoskeletal Symptoms: A Patient-Centered Approach